These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
117 related articles for article (PubMed ID: 32363767)
1. Hyaluronic-Acid-Presenting Self-Assembled Nanoparticles Transform a Hyaluronidase HYAL1 Substrate into an Efficient and Selective Inhibitor. Duan H; Donovan M; Hernandez F; Di Primo C; Garanger E; Schultze X; Lecommandoux S Angew Chem Int Ed Engl; 2020 Aug; 59(32):13591-13596. PubMed ID: 32363767 [TBL] [Abstract][Full Text] [Related]
2. Hyaluronidase 1 and hyaluronidase 2 are required for renal hyaluronan turnover. Colombaro V; Jadot I; Declèves AE; Voisin V; Giordano L; Habsch I; Flamion B; Caron N Acta Histochem; 2015 Jan; 117(1):83-91. PubMed ID: 25468725 [TBL] [Abstract][Full Text] [Related]
3. Stromal and epithelial expression of tumor markers hyaluronic acid and HYAL1 hyaluronidase in prostate cancer. Lokeshwar VB; Rubinowicz D; Schroeder GL; Forgacs E; Minna JD; Block NL; Nadji M; Lokeshwar BL J Biol Chem; 2001 Apr; 276(15):11922-32. PubMed ID: 11278412 [TBL] [Abstract][Full Text] [Related]
4. Elevated tissue expression of hyaluronic acid and hyaluronidase validates the HA-HAase urine test for bladder cancer. Hautmann SH; Lokeshwar VB; Schroeder GL; Civantos F; Duncan RC; Gnann R; Friedrich MG; Soloway MS J Urol; 2001 Jun; 165(6 Pt 1):2068-74. PubMed ID: 11371930 [TBL] [Abstract][Full Text] [Related]
5. Evaluation of the prognostic potential of hyaluronic acid and hyaluronidase (HYAL1) for prostate cancer. Posey JT; Soloway MS; Ekici S; Sofer M; Civantos F; Duncan RC; Lokeshwar VB Cancer Res; 2003 May; 63(10):2638-44. PubMed ID: 12750291 [TBL] [Abstract][Full Text] [Related]
6. Halting hyaluronidase activity with hyaluronan-based nanohydrogels: development of versatile injectable formulations. Montanari E; Zoratto N; Mosca L; Cervoni L; Lallana E; Angelini R; Matassa R; Coviello T; Di Meo C; Matricardi P Carbohydr Polym; 2019 Oct; 221():209-220. PubMed ID: 31227160 [TBL] [Abstract][Full Text] [Related]
7. Multivalent and multifunctional polysaccharide-based particles for controlled receptor recognition. Duan H; Donovan M; Foucher A; Schultze X; Lecommandoux S Sci Rep; 2018 Oct; 8(1):14730. PubMed ID: 30283149 [TBL] [Abstract][Full Text] [Related]
8. Hyaluronated nanoparticles with pH- and enzyme-responsive drug release properties. Kim SW; Oh KT; Youn YS; Lee ES Colloids Surf B Biointerfaces; 2014 Apr; 116():359-64. PubMed ID: 24521699 [TBL] [Abstract][Full Text] [Related]
9. Identification of bladder tumor-derived hyaluronidase: its similarity to HYAL1. Lokeshwar VB; Young MJ; Goudarzi G; Iida N; Yudin AI; Cherr GN; Selzer MG Cancer Res; 1999 Sep; 59(17):4464-70. PubMed ID: 10485499 [TBL] [Abstract][Full Text] [Related]
10. Monocytes/Macrophages Upregulate the Hyaluronidase HYAL1 and Adapt Its Subcellular Trafficking to Promote Extracellular Residency upon Differentiation into Osteoclasts. Puissant E; Boonen M PLoS One; 2016; 11(10):e0165004. PubMed ID: 27755597 [TBL] [Abstract][Full Text] [Related]
12. Plaque-hyaluronidase-responsive high-density-lipoprotein-mimetic nanoparticles for multistage intimal-macrophage-targeted drug delivery and enhanced anti-atherosclerotic therapy. Zhang M; He J; Jiang C; Zhang W; Yang Y; Wang Z; Liu J Int J Nanomedicine; 2017; 12():533-558. PubMed ID: 28144137 [TBL] [Abstract][Full Text] [Related]
13. Expression of tumor markers hyaluronic acid and hyaluronidase (HYAL1) in head and neck tumors. Franzmann EJ; Schroeder GL; Goodwin WJ; Weed DT; Fisher P; Lokeshwar VB Int J Cancer; 2003 Sep; 106(3):438-45. PubMed ID: 12845686 [TBL] [Abstract][Full Text] [Related]
14. On-Demand Antimicrobial Agent Release from Functionalized Conjugated Oligomer-Hyaluronic Acid Nanoparticles for Tackling Antimicrobial Resistance. Yuan Q; Zhao Y; Zhang Z; Tang Y ACS Appl Mater Interfaces; 2021 Jan; 13(1):257-265. PubMed ID: 33378174 [TBL] [Abstract][Full Text] [Related]
18. Selective delivery of PLXDC1 small interfering RNA to endothelial cells for anti-angiogenesis tumor therapy using CD44-targeted chitosan nanoparticles for epithelial ovarian cancer. Kim GH; Won JE; Byeon Y; Kim MG; Wi TI; Lee JM; Park YY; Lee JW; Kang TH; Jung ID; Shin BC; Ahn HJ; Lee YJ; Sood AK; Han HD; Park YM Drug Deliv; 2018 Nov; 25(1):1394-1402. PubMed ID: 29890852 [TBL] [Abstract][Full Text] [Related]
19. HYAL1 overexpression is correlated with the malignant behavior of human breast cancer. Tan JX; Wang XY; Li HY; Su XL; Wang L; Ran L; Zheng K; Ren GS Int J Cancer; 2011 Mar; 128(6):1303-15. PubMed ID: 20473947 [TBL] [Abstract][Full Text] [Related]
20. Detection of hyaluronidase activity using fluorescein labeled hyaluronic acid and Fluorescence Correlation Spectroscopy. Rich RM; Mummert M; Foldes-Papp Z; Gryczynski Z; Borejdo J; Gryczynski I; Fudala R J Photochem Photobiol B; 2012 Nov; 116():7-12. PubMed ID: 23018154 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]